特宝生物(688278)派格宾布局持续拓展，大单品展现广阔空间

兴业证券07-17

投资要点事件：公司公告派格宾(聚乙二醇干扰素α-2b注射液)新增适应症“原发性血小板增多症”的《药物临床试验批准通知书》。公司公告派格宾联合核苷(酸)类似物适用于临床治愈成人慢性乙型肝炎的增加适应症的上市许可申请被CDE纳入拟优先审评品种公示名单。点评：派格宾在乙肝治愈证据日益展现的情况下销售额持续快速增长，乙肝慢治愈适应症上市申请获得受理，有望带动产品空间的进一步提升，原发性血小板增多症相关临床...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2452690944?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-17 12:16","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2452690944","market":"sh","top_or_hot":-1,"title":"特宝生物(688278)派格宾布局持续拓展，大单品展现广阔空间","media":"兴业证券","content":"<div>\n<p>投资要点事件：公司公告派格宾(聚乙二醇干扰素α-2b注射液)新增适应症“原发性血小板增多症”的《药物临床试验批准通知书》。公司公告派格宾联合核苷(酸)类似物适用于临床治愈成人慢性乙型肝炎的增加适应症的上市许可申请被CDE纳入拟优先审评品种公示名单。点评：派格宾在乙肝治愈证据日益展现的情况下销售额持续快速增长，乙肝慢治愈适应症上市申请获得受理，有望带动产品空间的进一步提升，原发性血小板增多症相关临床...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071712293895cc5c23&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>特宝生物(688278)派格宾布局持续拓展，大单品展现广阔空间</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n特宝生物(688278)派格宾布局持续拓展，大单品展现广阔空间\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-17 12:16 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071712293895cc5c23&s=b><strong>兴业证券</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>投资要点事件：公司公告派格宾(聚乙二醇干扰素α-2b注射液)新增适应症“原发性血小板增多症”的《药物临床试验批准通知书》。公司公告派格宾联合核苷(酸)类似物适用于临床治愈成人慢性乙型肝炎的增加适应症的上市许可申请被CDE纳入拟优先审评品种公示名单。点评：派格宾在乙肝治愈证据日益展现的情况下销售额持续快速增长，乙肝慢治愈适应症上市申请获得受理，有望带动产品空间的进一步提升，原发性血小板增多症相关临床...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071712293895cc5c23&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688278","symbol_name":"特宝生物","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071712293895cc5c23&s=b","article_id":"2452690944","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071712293895cc5c23&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2452690944","pubTimestamp":1721189809,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"盈利预测与估值：公司是中国聚乙二醇蛋白质长效药物领域的领军企业，派格宾持续展现乙肝治愈证据，有望通过渗透率提升和适应症拓展持续打开空间，佩金、长效生长激素等产品有望未来为公司的长期增长提供保障。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688278":"特宝生物","BK0239":"医药制造"},"translate_title":"Tebao Biotech (688278) Pegabin's layout continues to expand, and large single products show broad space","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688278":1},"content_text":"投资要点事件：公司公告派格宾(聚乙二醇干扰素α-2b注射液)新增适应症“原发性血小板增多症”的《药物临床试验批准通知书》。公司公告派格宾联合核苷(酸)类似物适用于临床治愈成人慢性乙型肝炎的增加适应症的上市许可申请被CDE纳入拟优先审评品种公示名单。点评：派格宾在乙肝治愈证据日益展现的情况下销售额持续快速增长，乙肝慢治愈适应症上市申请获得受理，有望带动产品空间的进一步提升，原发性血小板增多症相关临床也有望从适应症扩展的维度带来增量。公司在研管线进展顺利，佩金、长效生长激素有望为公司的长期增长带来保障。盈利预测与估值：公司是中国聚乙二醇蛋白质长效药物领域的领军企业，派格宾持续展现乙肝治愈证据，有望通过渗透率提升和适应症拓展持续打开空间，佩金、长效生长激素等产品有望未来为公司的长期增长提供保障。我们看好公司的长期发展，预计公司2024-2026年EPS分别为1.86、2.52、3.41元，对应2024年07月15日收盘价，PE估值分别为30.3、22.3、16.5倍，首次覆盖，给予“增持”评级。风险提示：药品集中采购风险，新药研发风险，产品竞争格局加剧风险。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2452690944"}